NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
31 March 2025
| Name: | LUMOS DIAGNOSTICS HOLDINGS LIMITED (LDX) |
| ISIN: | AU0000157091 |
| Date of Listing: | 05 July 2021 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
This is a current registered entity, not in any form of external administration to our knowledge.Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Lumos Diagnostics Holdings Limited will be lifted immediately following the release by LDX of an announcement regarding a response to regulatory feedback received in relation to FebriDx. | 11/07/2022 |
The US FDA advised Lumos Diagnostics that, following its review of Lumos' 510(k) application, FebriDx did not demonstrate substantial equivalence to the predicate device and consequently has not been granted clearance for marketing in the U.S. The Company is currently reviewing the feedback provided by the FDA in order to determine the next steps. | 11/07/2022 |
The securities of Lumos Diagnostics Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of LDX, pending the release of an announcement regarding a response to regulatory feedback received in relation to FebriDx. | 08/07/2022 |
The suspension of trading in the options of Lumos Diagnostics Holdings Limited will be lifted immediately. | 01/07/2022 |
The company releases an Appendix 2A. | 30/06/2022 |
The options of Lumos Diagnostics Holdings Limited will be suspended immediately, in accordance with Listing Rule 17.3, as deferred settlement trading will not be made available for them, as noted in LDX's Prospectus, announced to the market on 6 June 2022. The options are expected to be quoted on a normal settlement basis on Friday, 1 July 2022. The suspension only applies to the LDX's options (ASX: LDXO), and does not apply to any other quoted securities of LDX. | 24/06/2022 |
listed entity carried for record purposes only | 05/07/2021 |
The suspension of trading in the securities of Lumos Diagnostics Holdings Limited will be lifted immediately following the release by LDX of an announcement regarding a response to regulatory feedback received in relation to FebriDx. | 11/07/2022 |
The US FDA advised Lumos Diagnostics that, following its review of Lumos' 510(k) application, FebriDx did not demonstrate substantial equivalence to the predicate device and consequently has not been granted clearance for marketing in the U.S. The Company is currently reviewing the feedback provided by the FDA in order to determine the next steps. | 11/07/2022 |
The securities of Lumos Diagnostics Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of LDX, pending the release of an announcement regarding a response to regulatory feedback received in relation to FebriDx. | 08/07/2022 |
The suspension of trading in the options of Lumos Diagnostics Holdings Limited will be lifted immediately. | 01/07/2022 |
The company releases an Appendix 2A. | 30/06/2022 |
The options of Lumos Diagnostics Holdings Limited will be suspended immediately, in accordance with Listing Rule 17.3, as deferred settlement trading will not be made available for them, as noted in LDX's Prospectus, announced to the market on 6 June 2022. The options are expected to be quoted on a normal settlement basis on Friday, 1 July 2022. The suspension only applies to the LDX's options (ASX: LDXO), and does not apply to any other quoted securities of LDX. | 24/06/2022 |
listed entity carried for record purposes only | 05/07/2021 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 11/06/2024 | Catherine Robson | 312,500 | $0.034 | $10,625 |
| 07/06/2024 | Sam Lanyon | 250,000 | $0.030 | $7,500 |
| 18/10/2023 | Doug Ward | 250,000 | $0.087 | $21,645 |
| 02/12/2022 | Catherine Robson | 208,332 | $0.049 | $10,269 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Sam Lanyon | Executive Chairman, Interim CEO | 05/07/2021 |
| Doug Ward | Managing Director, CEO | 21/06/2022 |
| Barrie Lambert | CFO | 16/02/2022 |
| Bronwyn Le Grice | Non Exec Director | 05/07/2021 |
| Lawrence Mehren | Non Exec Director | 05/07/2021 |
| Catherine Robson | Non Exec Director | 05/07/2021 |
| Tracy Weimar | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Rob Sambursky | Executive | 05/07/2021 | 13/04/2022 |
| Melanie Leydin | CFO, Company Secretary | 05/07/2021 | 16/02/2022 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
